Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2022-04-21
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Single and Multiple Ascending Doses of H021 in Healthy Participants
NCT06627556
A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis
NCT04457960
A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis
NCT02985593
First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers
NCT03482648
A Study of LIV001 in Healthy Subjects and Those with Mild-to-Moderate Active Ulcerative Colitis (UC)
NCT05975047
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Dose A
INV-101
subjects will be randomized 3:1 ratio
B
Dose B
INV-101
subjects will be randomized 3:1 ratio
C
Dose C
INV-101
subjects will be randomized 3:1 ratio
D
Dose D
INV-101
subjects will be randomized 3:1 ratio
E
Dose E
INV-101
subjects will be randomized 3:1 ratio
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
INV-101
subjects will be randomized 3:1 ratio
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit.
Exclusion Criteria
* History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
19 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Innovo Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minjeong Kim, Master
Role: STUDY_DIRECTOR
New Drug development Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Innovo Therapeutics, Inc.
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INV101-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.